Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00566449 · ClinicalTrials.gov registry record · Phase 2

A Safety and Effectiveness Study of JNJ-31001074 in Adults With Attention-Deficit/Hyperactivity Disorder.

A Phase 2 study of Attention Deficit Hyperactivity Disorder, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..

Completed
Registry status
Phase 2
Development phase
32
Enrollment target
20
Study locations

NCT00566449 is a Phase 2 study of Attention Deficit Hyperactivity Disorder that has completed, run by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. The registered enrollment target is 32 participants, below the 206-participant average among 88 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (84% lower). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00566449, a Phase 2 study of Attention Deficit Hyperactivity Disorder, has completed, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..

COMPLETED
Registry status
Phase 2
Development phase
32 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the safety and effectiveness of JNJ-31001074 compared to placebo in adults with Attention Deficit Hyperactivity Disorder (ADHD).

Conditions Studied

Attention Deficit Hyperactivity Disorder

Interventions

  • DRUG Placebo
  • DRUG JNJ-31001074

Study Locations (20)

Florida

  • - Bradenton
  • - Fort Myers
  • - Orlando
  • - South Miami

California

  • - Irvine
  • - Lafayette
  • - San Francisco

North Carolina

  • - Chapel Hll
  • - Raleigh

Texas

  • - Austin
  • - Houston

Idaho

  • - Eagle

Illinois

  • - Libertyville

Kansas

  • - Overland Park

Massachusetts

  • - Boston

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2007-12
Est. Completion 2008-07
Phase Phase 2

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

102 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00566449

The ClinicalTrials.gov registry entry for NCT00566449 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 206-participant average among 88 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (84% lower). The listed sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Attention Deficit Hyperactivity Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00566449 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Florida, California, North Carolina.

Frequently Asked Questions

What is clinical trial NCT00566449 about?

NCT00566449 is a clinical study titled "A Safety and Effectiveness Study of JNJ-31001074 in Adults With Attention-Deficit/Hyperactivity Disorder.". The purpose of this study is to evaluate the safety and effectiveness of JNJ-31001074 compared to placebo in adults with Attention Deficit Hyperactivity Disorder (ADHD).

What is the current status of trial NCT00566449?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2007-12. Estimated completion is 2008-07.

What conditions does trial NCT00566449 study?

This clinical trial studies the following conditions: Attention Deficit Hyperactivity Disorder.

What interventions are being tested in trial NCT00566449?

The interventions under investigation include: Placebo (DRUG), JNJ-31001074 (DRUG).

Who is sponsoring clinical trial NCT00566449?

This trial is sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00566449 being conducted?

This trial has 20 study locations across California, Florida, Idaho, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Attention Deficit Hyperactivity Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Attention Deficit Hyperactivity Disorder

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.